Celastrol enhanced the anticancer effect of lapatinib in human hepatocellular carcinoma cells in vitro

Journal of B.U.ON.

Volumn 19, Issue 2, 2014, Pages 412-418

  Yan, Yan Yan ^a   Guo, Yan ^b   Zhang, Wei ^b,c   Ma, Cun Gen ^a   Zhang, Yan Xia ^a   Wang, Chen ^b   Wang, Hai Xia ^b  

^a SHANXI DATONG UNIVERSITY   (China)

^b Wuhai Municipal People's Hospital   (China)

^c BAOTOU MEDICAL COLLEGE   (China)

Author keywords

Celastrol; EGFR; HepG2; Lapatinib; Synergy

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CELASTROL; LAPATINIB; VASCULOTROPIN RECEPTOR;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURFACE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GROWTH INHIBITION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; MTT ASSAY; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG SYNERGISM; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRITERPENES;

EID: 84904185887     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kew MC. Epidemiology of hepatocellular carcinoma. Toxicology 2002;181:35-38. (Pubitemid 36015669)
2. Chau GY, Lui WY, Tsay SH, Chao Y, King KL, Wu CW. Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: A case-control study. Ann Surg Oncol 2006;13:1329-1337. (Pubitemid 44435799)
3. Lo CM, Liu CL, Chan SC et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-842. (Pubitemid 46809282)
4. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
5. Sharma SV, Bell DW, Settleman J, Haber DA Epidermal growth factor receptor mutations in lung cancer. Nat Rev 2007;7:169-181.
6. Avizienyte E, Ward RA, Gamer AP. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 2008;415:197-206.
7. Kiaei M, Kipiani K, Petri S, Chen J, Calingasan NY, Beal MF. Celastrol blocks neuronal cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:246-254. (Pubitemid 43805908)
8. Li H, Zhang YY, Tan HW, Jia YF, Li D. Therapeutic effect of tripterine on adjuvant arthritis in rats. J Ethnopharmacol 2008;118:479-484.
9. Abbas S, Bhoumik A, Dahl R et al. Preclinical studies of celastrol and acetyl isogambogic acid in melanoma. Clin Cancer Res 2007;13:6769-6778. (Pubitemid 350206815)
10. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008;264:101-106.
11. Guo Y, Zhang W, Yan YY et al. Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction. J BUON 2013;18:477-485.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
13. Dai CL, Tiwari AK, Wu CP et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008;68:7905-7914.
14. Yan YY, Zheng LS, Zhang X et al. Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Mol Pharm 2011;8:1687-1697.
15. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002;7:d376-389.
16. Normanno N, De Luca A, Bianco C et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
17. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol 2006;17:ii46-48.
18. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-867. (Pubitemid 36833877)
19. Setty AR, Sigal LH. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheu 2005;34:773-784. (Pubitemid 40732452)
20. Lee JH, Koo TH, Yoon H et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006;72:1311-1321. (Pubitemid 44572192)
21. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006;66:4758-4765.